ST. LOUIS, June 9, 2015 /PRNewswire/ -- Sigma-Aldrich
Corporation (NASDAQ: SIAL) announced today that the
Cerilliant® brand within its Applied Diagnostics and
Testing business unit has introduced five new stable-labeled
internal standards of the antifungal agents fluconazole,
itraconazole, ketoconazole, posaconazole, and voriconazole at 1.0
mg/mL concentrations.
Antifungal agents offer critically ill or
immunocompromised patients multiple treatment options against
invasive fungal infections. The use of antifungals can,
however, impact drug metabolism and drug interactions due to their
ability to act as a substrate or inhibitor of cytochrome P450 (CYP)
metabolic enzymes2, 3 thus presenting several
clinical challenges including interactions with
co-administered drugs, concentration-dependent toxicity, and
variations in drug absorption and metabolism.
Therapeutic drug monitoring (TDM) by
LC-MS/MS is considered for antifungal drugs to
avoid such adverse clinical outcomes and to ensure
effectiveness of the drug regimen.1, 2
Cerilliant's solution certified reference materials offer
clinical and diagnostic testing labs, hospitals, and
bioanalytical/PKDM labs a full selection of internal standards for
quantitation of the most common antifungal drugs in serum or plasma
by mass spectrometry-based analytical methods. The deuterium or
13C substitutions of each internal standard were
carefully chosen to conserve a minimum [M+3] separation from the
unlabeled drug in the major ion fragments used in LC-MS/MS
antifungal TDM applications and metabolism studies.
These new internal standards complement Cerilliant's diverse
catalog offering of triazole, imidazole, and other azole antifungal
Certified Spiking Solutions®. Coming soon, Cerilliant
will also introduce stable-labeled internal standards for the
antifungal metronidazole and active metabolite
hydroxyitraconazole. Cerilliant certified reference solutions
are manufactured and certified to the highest industry standards
including ISO Guide 34, ISO/IEC 17025, and ISO 13485 and are
compliant with ISO 15194.
About Cerilliant: Cerilliant Corporation, located in
Round Rock, Texas, is a global
leader in providing certified reference standards for critical
applications. The company has been providing Certified Reference
Materials for over 30 years. Cerilliant offers more than 3,000
catalog products and a full range of custom products and services
that address the stringent and complex requirements of the
pharmaceutical, clinical diagnostic, clinical/forensic toxicology,
and natural products industries. Cerilliant sustains a modern,
robust quality system, which incorporates cGMP, GLP, and ISO
requirements. The company is accredited to ISO Guide 34 and ISO/IEC
17025, is certified to ISO 13485 and ISO 9001:2008, and is
compliant with ISO 17511 and ISO 15194. Cerilliant Corporation is a
subsidiary of Sigma-Aldrich. For more information about Cerilliant,
visit www.cerilliant.com.
About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology
company focused on enhancing human health and safety, manufactures
and distributes 250,000 chemicals, biochemicals and other essential
products to more than 1.4 million customers globally in research
and applied labs as well as in industrial and commercial markets.
With three distinct business units - Research, Applied and SAFC
Commercial - Sigma-Aldrich is committed to enabling science to
improve the quality of life. The Company operates in 37 countries,
has approximately 9,300 employees worldwide and had sales of
$2.79 billion in 2014.
For more information about Sigma-Aldrich, visit
www.sigma-aldrich.com.
Sigma-Aldrich, Cerilliant,
Snap-N-Spike, and Certified Spiking Solutions are registered
trademarks of Sigma-Aldrich Co. LLC or an affiliated company.
- Dismukes WE (2000) Clin. Infect. Dis. 30:653-657
- Bruggemann RJM, Alffenaar J-W C, Blijlevens NMA, Billaud EM,
Kosterink JGW, Verweij PE, Burger DM, Saravolatz LD (2009)
Clin. Infect. Dis. 48 (10):1441-1458
- "Antifungal Drug Monitoring." Accessed 4
May 2015 from
http://www.mayomedicallaboratories.com/articles/communique/2010/11.html
- Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF,
Sellers EM (2002) Drug Metab. Dispos. 30
(03):314-318
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cerilliant-introduces-snap-n-spike-stable-labeled-internal-standards-of-antifungal-agents-300095796.html
SOURCE Sigma-Aldrich Corporation